title: Expression of human CD1d molecules protects target cells from NK cell-mediated cytolysis.
abstract: The cytotoxic activity of NK cells can be inhibited by classical and nonclassical MHC molecules. The CD1 system is formed by a family of glycoproteins that are related to classical MHC. CD1a, b, and c molecules present lipids or glycolipids to T cells and are involved in defense against microbial infections, especially mycobacteria. It has been shown recently that these molecules can inhibit target cell lysis by human NK cells. It has also been shown that mouse CD1d molecules can protect cells from NK cell-mediated cytotoxicity. In the present study, we describe how human CD1d, orthologous to murine CD1 molecules, can inhibit NK cell-mediated cytolysis. We have expressed CD1d in the HLA class I-deficient cell lines L721.221 and C1R. The inhibitory effect is observed when effector NK cells from different donors are used, as well as in different cell lines with NK activity. The inhibitory effect was reversed by incubating the target cells with a mAb specific for human CD1d. Incubation of target cells with the ligands for CD1d, alpha-galactosylceramide (alpha-GalCer), and beta-GalCer abolishes the protective effect of CD1d in our in vitro killing assays. Staining the effector cells using CD1d tetramers loaded with alpha-GalCer was negative, suggesting that the putative inhibitory receptor does not recognize CD1d molecules loaded with alpha-GalCer.
authors.affiliation: Unidad de Inmunología, Facultad de Medicina, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain.
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Campos-Martín
authors.forename: Manuel
authors.initials: M
authors.lastname: Gómez del Moral
authors.forename: Beatriz
authors.initials: B
authors.lastname: Gozalbo-López
authors.forename: Javier
authors.initials: J
authors.lastname: Suela
authors.forename: Eduardo
authors.initials: E
authors.lastname: Martínez-Naves
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D018949:Antigens, CD1 / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D055610:Antigens, CD1d; D018938:Caco-2 Cells; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005699:Galactosylceramides / Q000494:pharmacology; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D020011:Protective Agents; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D018949:Antigens, CD1; D055610:Antigens, CD1d; C526877:CD1D protein, human; D005699:Galactosylceramides; D015395:Histocompatibility Antigens Class I; D020011:Protective Agents